Citius Oncology, Inc. CTOR Reimburse Amount
Reimburse Amount at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:ReimburseAmount.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s reimburse amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s reimburse amount?
- Citius Oncology, Inc. (CTOR) reported reimburse amount of $2.65M in Q4 2025.
- How has Citius Oncology, Inc.'s reimburse amount changed year-over-year?
- Citius Oncology, Inc.'s reimburse amount decreased by 0.0% year-over-year, from $2.65M to $2.65M.
- What does reimburse amount mean?
- Reflects the cash received or paid to settle claims or expenses that were previously covered by another party, such as insurance recoveries or partner cost-sharing arrangements. This metric helps in understanding the net impact of non-operating or shared-cost activities on the company's cash position. It is useful for isolating core operational performance from one-time or recoverable expenses.